rodman renshaw report on onty

For definitions and the distribution of analyst ratings, and other disclosures, please refer to pages 14 - 15 of this report.

®

March 9, 2012

Oncothyreon Inc. (ONTY)EARNINGS UPDATE

LIFE SCIENCES

Market Outperform / Speculative Risk

Reni Benjamin, Ph.D.212-430-1743

[email protected]

4Q11 UPDATE – ONCOTHYREON DOWN BUT NOT OUT – PX-866 TO DRIVE VALUE IN 2012

MARKET DATA 3/8/2012

Price $5.20Exchange NASDAQTarget Price $10.0052 Wk Hi - Low $11.59 - $3.13Market Cap(MM) $222.0EV(MM) $167.3Shares Out (MM) 42.7Public Mkt Float (MM) 25.7Avg. Daily Vol 1,238,149Short Interest 13,407,580

BALANCE SHEET METRICS

Cash (MM) $33.2LTD (MM) $19.2Total Debt/Capital NACash/Share $1.29Book Value(MM) NABook Value/Share $0.85

EARNINGS DATA ($)

FY - Dec 2011E 2012E 2013EQ1 (Mar) (0.24) (0.18) --Q2 (Jun) (0.91) (0.19) --Q3 (Sep) 0.22 (0.22) --Q4 (Dec) (0.27) (0.25) --Full Year EPS (1.12) (0.84) --Revenue (MM) 0.2 0.0 --

VALUATION METRICS

EV/Sales

INDICES

DJIA 12,907.9SP-500 1,365.9NASDAQ 2,637.2NBI 1,237.9

Q1 Q2 Q3 Q12

4

6

8

10

12

2011 2012

1 Year Price History

Created by BlueMatrix

0

4

8

12

16

4Q11 FINANCIAL RESULTS For 4Q11, Oncothyreon reported a netloss of $11.5 MM or $(0.27) per diluted share, lower than our net lossestimate of $12.4 MM or $(0.30) per share, as a result of the fair value ofthe change in valuation of a warrant liability. At the end of 4Q11, thecompany had approximately $66 MM in cash and cash equivalents. Thetotal cash position should be sufficient, in our opinion, to fund operationsthrough 2013.

START TRIAL TO PROCEED TO FINAL ANALYSIS Recenlty, during a4Q11 earnings call, Oncothyreon’s partner, Merck KGaA (MRK.DE, NotRated), announced that the second interim analysis of the Phase 3Stimuvax START trial in Non-small Cell Lung Cancer (NSCLC) wasconducted by an independent Data Monitoring Committee (DMC). Theanalysis revealed no issues, and the committee recommended that thetrial continue to its final analysis with top-line data now expected in 2013(previously was the end of 2012). The second interim analysis wasscheduled when 529 or 75% of the events occurred During the 4Q11call, Oncothyreon’s management emphasized that the outcome of thesecond interim analysis was “good” as it also implies that the trial is notfutile.

PX-866 – IN THE DRIVING SEAT The company provided an update onthe four ongoing Phase 2 trials of PX-866: 1) a Phase 1/2 trial incombination with docetaxel in patients with NSCLC and head & neckcancer, 2) a Phase 1/2 trial in combination with Erbitux in colorectal andhead & neck cancers, 3) an open-label Phase 2 trial evaluating PX-866monotherapy in relapsed glioblastoma multiforme (GBM), and 4) asingle-arm, open-label Phase 2 trial evaluating PX-866 monotherapy incastrate-resistant prostate cancer (CRPC) patients naïve tochemotherapy. The key events for 2012 include the availability of thepreliminary data from the GBM trial at the upcoming annual AmericanSociety of Clinical Oncology (ASCO) meeting as well as completion ofenrollment and preliminary results from the randomized studies by yearend 2012.

INVESTMENT OPINION We are reiterating our Market Outperformrating and 12-month price target of $10 per share for Oncothyreon. Ourprice target is based on a 2015 discounted revenues and earnings pershare multiples analysis. Although the second interim analysis did notlive up to investor’s expectations, we continue to believe in the Stimuvaxstory. The recent data highlights the therapeutic value of Stimuvax, andalso serves to validate Oncothyreon’s MUC1 based vaccine technologyplatform. In addition to Stimuvax and ONT-10, Oncothyreon possesses abroad oncology pipeline, which includes PX-866 (an irreversible inhibitorof PI3K) and ONT-701 (a newly acquired pan Bcl-2 inhibitor).

2RODMAN & RENSHAW EQUITY RESEARCH

INVESTMENT SUMMARY Oncothyreon, headquartered in Bellevue, WA and founded in 1985, is a biotechnology company focused on the development of oncology drugs. The company’s lead program is Stimuvax, a therapeutic cancer vaccine targeting the MUC-1 protein, which is licensed to Merck KGaA (MRK.DE, Not Rated). Importantly, Oncothyreon is entitled to $90 MM in additional milestones and mid-double digit royalties on sales. Stimuvax is currently being evaluated in two Phase 3 trials for the treatment of non-small cell lung cancer: 1) the 1514-patient START trial and 2) the 420-patient INSPIRE trial in Asian patients. The first interim look for the START trial occurred at YE10 and the DSMB permitted the trial to continue per protocol. A second interim look occurred recently in 1Q12 after 529 or 75% of the events occurred, and did not reveal any safety issues. Oncothyreon’s next most advanced development program is PX-866, an oral, irreversible, small molecule inhibitor of PI3 kinase, which the company is evaluating in a broad Phase 2 program in oncology. Oncothyreon is also developing ONT-10, a next generation therapeutic cancer vaccine candidate targeting MUC-1, for which an IND was filed in 4Q11 and initiation of a Phase 1 trial is slated for 1H12. Finally, in September 2011, Oncothyreon entered into a licensing agreement with the Sanford-Burnham Medical Research Institute for the preclinical compound sabutoclax, a pan-inhibitor of Bcl-2, now referred to as ONT-701.

UPDATE ON STIMUVAX Eagerly Awaited Second Interim Analysis Revealed No Surprises! On March 6, 2012, during the 4Q11 earnings call, Merck KGaA, Oncothyreon’s partner, announced that the second interim analysis of the Phase 3 Stimuvax START trial in Non-small Cell Lung Cancer (NSCLC) was conducted by an independent Data Monitoring Committee (DMC). The analysis revealed no issues, and the trial will continue to its final analysis as planned with top-line data now expected in 2013 (previously was the end of 2012). The second interim analysis was scheduled when 529 or 75% of the events occurred, and of note, included 156 patients that were enrolled after the hold on the trial was lifted. During the 4Q11 call, Oncothyreon’s management emphasized that the outcome of the second interim analysis was “good” as it also implies that the trial is not futile. Recall, the Phase 3 START trial recruited 1514 stage 3 NSCLC patients who achieved stable disease after at least two cycles of platinum-based radio-chemotherapy. The START trial is 90% powered to detect a hazard ratio of 0.77 (1-sided p-value 0.025) corresponding to a 6 month treatment effect with a 20-month overall survival assumed for the control arm. We do not see the outcome of the second interim look at surprising, as we were expecting this and have previously cautioned investors to exercise patience and wait until the interim results were announced.

STIMUVAX – A MUC1 CANCER VACCINE Oncothyreon’s most advanced product candidate is Stimuvax (L-BLP25), which is being developed in partnership Merck KGaA in Phase 3 trials. Stimuvax is a liposome-based vaccine technology derived from the human mucin 1 (MUC1) protein and offers an innovative approach to treating NSCLC by targeting this antigen. MUC1 is a transmembrane glycoprotein abundantly expressed in cancers of epithelial origin (Figure 1) and observed in approximately 75% of all tumors. Of importance, MUC1 is over-expressed and aberrantly glycosylated in NSCLC tumors. Stimuvax is composed of a 25 amino acid sequence of MUC1, plus a patented synthetic analog of lipid A, an immunoadjuvant, in a liposomal formulation. The vaccine is designed to induce a cellular immune response and lead to immune rejection of tumor cells in the lung that express the aberrantly glycosylated MUC1 antigen. In preclinical studies in mice, treatment with Stimuvax was characterized by a proliferative T-cell response to the MUC1 antigen and the production of interferon-gamma, indicative of a T-helper type 1 (Th1) response.

Oncothyreon Inc. March 9, 2012


Figure 1: Tumor-Associated Mucin is Targeted by Stimuvax

Source: Oncothyreon Reports

Phase 3 START Trial In January 2007, Oncothyreon and partner Merck KGaA initiated the Phase 3 START (Stimulating Targeted Antigenic Responses To NSCLC) trial evaluating Stimuvax. The trial is a randomized, double-blind, placebo-controlled study originally designed to enroll approximately 1300 second-line patients (enrollment completed with 1514 patients) with unresectable stage 3 NSCLC exhibiting locoregional disease who achieved a response or stable disease after at least two cycles of platinum-based radio-chemotherapy. Patients received weekly injections of Stimuvax for the first 8 weeks of the study, followed by injections every 6 weeks thereafter until disease progression. The primary endpoint of the trial is overall survival with time to symptom progression and time to disease progression as secondary endpoints. Of note, the trial was granted a Special Protocol Assessment (SPA) by the FDA which could potentially accelerate approval of Stimuvax should pre-specified clinical trial requirements be met. In December 2010, the company announced that the first interim look triggered by 353 events was completed and the Independent DMC recommended that the trial continue. The START trial is 90% powered to detect a hazard ratio of 0.77 (1-sided p-value 0.025) corresponding to a 6 month treatment effect with a 20-month overall survival assumed for the control arm. Management has not disclosed the alpha spend associated with the first and second interim looks. Phase 3 INSPIRE Trial In December 2009, Merck KGaA initiated a second Phase 3 trial evaluating Stimuvax in Asian patients with advanced NSCLC. The study is a randomized, double-blind, placebo-controlled trial enrolling approximately 420 patients with unresectable stage 3 NSCLC who have demonstrated either stable disease or an objective response following primary chemo-radiotherapy. The primary endpoint of the study is overall survival and the trial is enrolling patients in Taiwan, China, Hong Kong, Singapore, and South Korea. Top-line data for the INSPIRE study is not anticipated until 2014.

Prior FDA Clinical Hold In March 2010, the FDA placed the IND application for Stimuvax on hold and Merck KGaA/Oncothyreon temporarily suspended the worldwide clinical trials of Stimuvax. The hold was issued to determine the cause of a single case of encephalitis in an exploratory Phase 2 trial in multiple myeloma in which Stimuvax was used in combination with repeated dosing of cyclophosphamide, as opposed to the single dose used in the Phase 3 solid tumor setting. During the hold, both the Phase 3 NSCLC trials START and INSPIRE, as well as an additional trial in breast cancer called STRIDE, were suspended. In June 2010, the FDA lifted the clinical hold on Stimuvax and START and INSPIRE were re-started, along with a Phase 2 trial in NSCLC patients in Asia. However, the hold on the Phase 3 STRIDE trial in breast cancer was not lifted and Oncothyreon and Merck KGaA decided to close that study. As a result of the hold, 156 patients in the START study may have received a sub-therapeutic dose of Stimuvax because the hold overlapped with the initial 8 week portion of weekly dosing for these patients.



As a result, the FDA agreed to formally amend the SPA to permit the enrollment of an additional 156 patients to replace the 156 patients who may have received sub-therapeutic dosing. Investors should be aware that this amendment reflects a replacement of patients for the intent-to-treat analysis to maintain the prior powering assumptions for the study and does not reflect an increase in the sample size. Of note, the 156 patients who may have been sub-therapeutically dosed will remain as subjects in the safety database, but will not be counted towards the efficacy analysis. Encouraging Results from a Phase 2B Trial Oncothyreon reported results in April 2006 from a Phase 2 study evaluating Stimuvax as a treatment for NSCLC. In this study, conducted in Canada and the UK, 171 patients with stage IIIB or IV NSCLC who had stable disease were randomized to receive treatment with either subcutaneous Stimuvax 1000μg plus best supportive care (BSC) or BSC alone. Study endpoints were safety and survival, as monitored at 3-month intervals for 12 months, with quality of life and immune response as secondary endpoints. The results demonstrated a median overall survival of 17.4 months for patients treated with Stimuvax plus BSC versus 13.3 months for patients treated with BSC alone, with a 2-year survival rate of 43% for the Stimuvax arm versus 29% for the BSC arm (Figure 2). While the data were very promising, the treatment effect for Stimuvax did not reach statistical significance (p=0.066). However, the study was putatively adversely affected by variability in patient stratification. In addition, the control arm performed much better than would ordinarily be expected, with a median survival time of 13 months observed in the study versus an expected 7 months typically observed on BSC. The variance also can be partly explained by the higher than anticipated percentage of stage IIIB locoregional (LR) and therefore less advanced patients enrolled. Among patients with Stage IIIB NSCLC LR disease, a median survival of 30.3 months was observed in Stimuvax-treated patients, with an observed 2-year survival rate of 60% for patients treated with Stimuvax versus 37% for patients in the BSC arm (p = 0.069).

Figure 2: Stimuvax is Most Effective in Stage IIIB Locoregional Patients

Source: Rodman & Renshaw Research and Oncothyreon Reports

Although the difference was not statistically significant in this subset analysis, in our opinion these results were very encouraging, and compare favorably to results from currently marketed therapies such as OSI Pharmaceuticals’ (OSIP, Not Rated) Tarceva, which confers an improvement in survival of only 2 months. Additionally, more patients in the Stimuvax arm demonstrated either a clinically meaningful improvement or had stable disease as compared with patients in the BSC arm. These results prompted Oncothyreon and partner Merck KGaA to pursue further evaluation of Stimuvax in Phase 3 trials.

ASH 2011: Stimuvax Induces Immune Response In Multiple Myeloma Patients

Phase 2 Stimuvax Trial in Multiple Myeloma

At the 2011 American Society of Hematology meeting, Oncothyreon’s partner Merck KGaA presented data from a Phase 2 study of Stimuvax in patients with untreated asymptomatic multiple myeloma (MM) or with MM in a stable response phase following anti-tumor therapy. The primary objective of the Phase 2 study was to examine the immune response to Stimuvax. Patients were given Stimuvax weekly for 8 weeks, and then given a maintenance vaccination every 6 weeks until disease progression. Patients were randomized to receive a single dose of cyclophosphamide 3 days prior to the 1

st injection of Stimuvax (group A, n=17), or to receive multiple low dose cyclophosphamide treatments

throughout the Stimuvax treatment period (group B, n=17). The treatment duration was 54 weeks for group A vs. 87 weeks for group B.

Cohort Stimuvax + BSC (n=88) BSC (n=83)

Number of patients 88 83

Median overall survival time 17.4 months 13 months

2-yr survival rate 43.2% 28.9%

Number of patients 17 8

Median overall survival time 30.6 months 13.3 months

3-yr survival rate 49% 27%

Stage I I IB Locoregional:

Overall:



The first immune responses were detected ≤9 weeks into the study, and MUC1 immune response/augmentation was observed in 47% of patients in both group A and B. It is noteworthy that immune responses were similar between single vs. multiple cyclophosphamide dosages. In vitro analysis of peripheral blood mononuclear cells (PBMC) revealed that the majority of patients displayed a cytokine profile consistent with a type 1 immune response to MUC1 peptides.

Stimuvax Treatment Generates Long-Term Stabilization of Disease

Objective clinical responses were not observed according to Blade Criteria, which requires a ≥50% reduction in serum myeloma (M) protein and ≥90% reduction of urine M protein on at least two tests for a minimum of 6 weeks. However, a reduction in M protein concentration, when compared to pretreatment levels, was observed in 13 of the 29 evaluable patients across both group A and B. A drop in M protein was observed in 9 out of 12 patients that did not receive prior treatment, as compared to a decrease in M protein in 4 of 17 patients that received prior treatment. Overall, the decrease in M protein concentration indicates that Stimuvax may have a potential clinical benefit in a subset of patients, and the data also indicates that patients without prior treatment are most likely to respond to Stimuvax.

UPDATE ON NEXT GENERATION STIMUVAX - ONT-10

ONT-10 Moving Towards Phase 1 Trial

In 4Q11, Oncothyreon announced the submission of an Investigational New Drug (IND) application for ONT-10. ONT-10, a follow-up to Stimuvax, is a fully synthetic liposomal glycolipopeptide cancer vaccine designed to treat cancers over-expressing MUC1.

ONT-10 consists of a 43 amino acid glycoprotein sequence of MUC-1, combined with a synthetic form of PET (penta erythritol)-lipid A, a toll like receptor 4 agonist designed to produce both a cellular and humoral response, and therefore elicit a multi-dimensional attack on cancer cells. Following a successful review of the IND, Oncothyreon plans initiate an ONT-10 Phase 1 trial in 1H12. Oncothyreon currently retains all the rights related to ONT-10, and Oncothyreon has indicated an intention to seek partners for this program. Of note, Merck KGaA has a right of first negotiation with regard to a future licensing agreement for ONT-10. Oncothyreon is developing a follow on therapeutic vaccine, ONT-10, a fully synthetic MUC1-based liposomal glycolipopeptide cancer vaccine for the treatment of cancer. ONT-10 is composed of a 43 amino acid glyocoprotein sequence of the cancer-associated protein MUC-1. The ONT-10 adjuvant is a fully synthetic form of PET (penta erythritol)-lipid A differing from the Stimuvax adjuvant in that PET-lipid A is designed to produce both a cellular and humoral response and thus elicit a multi-pronged attack on cancer cells (Figure 3).

Figure 3: ONT-10 Stimulates Both Arms of the Immune System

Source: Oncothyreon

Because ONT-10 contains fragments derived from the peptide and the carbohydrate, it can stimulate the immune system to attack multiple parts of the mucin protein, thus potentially stimulating a more robust immune response against mucin.



MARKET POTENTIAL FOR STIMUVAX We have created a market model to project future sales of Stimuvax for the treatment of NSCLC in the US and the EU (Figure 4). Additional indications that Merck KGaA might pursue beyond NSCLC represent upside not included in our model. With the potential for BLA and MAA filings for Stimuvax by Merck KGaA in 2013 and FDA and EMA approvals by 2H13 and 1H14, respectively, our model assumes US and EU launches in 2H13 and 1H14, respectively. Of note, we believe that Stimuvax could significantly penetrate the 2

nd and 3

rd-line NSCLC settings, with some off-label penetration

possible in the 1st-line setting. In the US, we have modeled a net royalty rate of 12% to Oncothyreon which takes into

account a mid-single digit royalty payable by Oncothyreon to the original licensor of the MUC1 antigen, the patent for which expires in 2018. The royalty rate is higher in the US to compensate for Oncothyreon’s relinquishing of the company’s prior co-promotion interest in US and Canadian sales. In the EU, we have modeled a slightly lower royalty rate of 9%. We believe that an annual cost of therapy could be priced at $50K in the US and somewhat lower, $35K, in the EU. Of note, potential for additional revenues for patients receiving Stimuvax beyond the first year of therapy, which would generate approximately $25K per patient, represents additional upside not included in our market model. To account for additional commercial risk from potential competitors, we risk-adjust the total US and EU royalty revenues by 85%. Based on our model, we forecast risk-adjusted royalties to Oncothyreon of approximately $16.1 MM in the year of launch, ramping up to $125.4 MM by 2015. Of note, we do not include the potential for Japanese sales in our market model as the INSPIRE trial is only expected to readout top-line data in 2014.

Figure 4: Market Model for Stimuvax

Sources: Rodman & Renshaw Research

2013 2014 2015

Non-Small Cell Lung Cancer (NSCLC), US

Prevalence 160,351 161,954 163,574

1st-Line Patients 112,246 113,368 114,502

2nd and 3rd-Line Patients 39,286 39,679 40,076

Penetration

1st-Line Patients 1% 6% 8%

2nd and 3rd-Line Patients 3% 8% 18%

Patient Numbers

1st-Line Patients 1,122 6,802 9,160

2nd and 3rd-Line Patients 982 3,174 7,214

Potential Number of NSCLC Patients on Stimuvax 2,105 9,976 16,374

Annual Cost of Therapy 50,000$ 50,000$ 50,000$

Merck KGaA Stimuvax Sales in NSCLC, US 105,230$ 498,818$ 818,688$

Royalties from Merck KGaA on Net Sales 12,628$ 59,858$ 98,243$

Non-Small Cell Lung Cancer (NSCLC), EU

Prevalence 153,147 154,678 156,225

1st-Line Patients 107,203 108,275 109,358

2nd and 3rd-Line Patients 37,521 37,896 38,275

Penetration

1st-Line Patients 1% 6% 8%

2nd and 3rd-Line Patients 3% 8% 18%

Patient Numbers

1st-Line Patients 1,072 6,496 8,749

2nd and 3rd-Line Patients 938 3,032 6,890

Potential Number of NSCLC Patients on Stimuvax 2,010 9,528 15,638

Annual Cost of Therapy 35,000$ 35,000$ 35,000$

Merck KGaA Stimuvax Sales in NSCLC, EU 70,352$ 333,486$ 547,334$

Royalties from Merck KGaA on Net Sales, EU 6,332$ 30,014$ 49,260$

Total Stimuvax Revenues to Merck KGaA 175,582$ 832,304$ 1,366,022$

Total Royalties from Merck KGaA to ONTY 18,959$ 89,872$ 147,503$

Total Risk-Adjusted Royalties from Merck KGaA to ONTY 16,115$ 76,391$ 125,377$



UPDATE ON PX-866 PI3-KINASE INHIBITOR PROGRAM

PX-866 – IN THE DRIVING SEAT The company provided an update on the four ongoing Phase 2 trials of PX-866: 1) a Phase 1/2 trial in combination with docetaxel in patients with NSCLC and head & neck cancer, 2) a Phase 1/2 trial in combination with Erbitux in colorectal and head & neck cancers, 3) an open-label Phase 2 trial evaluating PX-866 monotherapy in relapsed glioblastoma multiforme (GBM), and 4) a single-arm, open-label Phase 2 trial evaluating PX-866 monotherapy in castrate-resistant prostate cancer (CRPC) patients naïve to chemotherapy. The key events for 2012 include the availability of the preliminary data from the GBM trial at the upcoming annual American Society of Clinical Oncology (ASCO) meeting as well as completion of enrollment and preliminary results from the randomized studies by year end 2012. . PX-866 DATA HIGHLIGHTED AT AACR-NCI-EORTC – A PIPELINE EMERGES

PX-866 + Docetaxel Shows Long Lasting Responses – Patients Still Being Treated

Recently, Oncothyreon presented data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from the Phase 1/2 combination trial of PX-866 and docetaxel. The Phase 1 portion of the trial enrolled 43 patients with advanced cancer. Patients were treated at 3 different doses of daily PX-866 in combination with 1 dose of docetaxel (75 mg/m

2 every 3 weeks). The Phase 1 treatment schedule did not produce any dose limiting

toxicities, and the recommended daily dose of PX-866 in combination with docetaxel was determined to be 8 mg.

The combination therapy resulted in mainly Grade 1/2 adverse advents, but 4 patients reported treatment-related serious adverse events. Of 28 patients eligible for response analysis, the best response was stable disease (n=21, 75%). Of note, 8 patients have received at least 7 treatment cycles and 20 patients currently remain in the trial. Also noteworthy, the data indicated a trend towards clinical benefit in patients who contained a mutated PIK3CA gene.

In October 2011, Oncothyreon initiated the Phase 2 portion of the PX-866 trial in combination with docetaxel in patients with advanced cancers. Based on the Phase 1 data, the recommended daily dose of PX-866 in combination with docetaxel was determined to be 8 mg. Oncothyreon has indicated that the combination of PX-866 / docetaxel was well tolerated and associated with disease control, with more complete data to be released at an upcoming scientific meeting. The Phase 2 portion of the trial will be an open-label, randomized trial of anti-tumor activity and safety of the recommend dose of PX-866 and docetaxel compared to docetaxel alone. The Phase 2 trial will examine two groups of patients for a total of 170 patients. Group 1 will consist of 2

nd or 3

rd line NSCLC patients. Group 2 will consist of patients

who have failed previous therapy for metastatic squamous cell carcinoma of the head and neck. Oncothyreon plans to enroll 88 patients in Group 1 and 82 patients in Group 2. The primary endpoint of the Phase 2 portion of the trial is progression free survival, and the secondary endpoints will examine objective response rate and overall survival.

PX-866 + Cetuximab Data Just as Compelling

Also at the AACR-NCI-EORTC meeting, Oncothyreon presented data from the Phase 1 portion of the Phase 1/2 trial of PX-866 in combination with cetuximab (an EGFR inhibitor) in patients with either incurable metastatic colorectal carcinoma or incurable squamous cell carcinoma of the head and neck. The trial enrolled 11 patients and treated patients at 2 different doses of PX-866 in combination with a standard weekly dose of cetuximab. The Phase 1 treatment schedule did not produce any dose limiting toxicities, and the recommended daily dose of PX-866 in combination with cetuximab was determined to be 8 mg. The combination therapy resulted in mainly Grade 1/2 adverse advents, however, 2 patients reported treatment-related serious adverse events. Of the patients evaluated for response, 4 patients had a partial response (50%), 3 patients had stable disease (38%), and 1 patient had progressive disease (13%), which corresponds to a disease control rate of 88%. Of note, 5 of the evaluated patients had prior treatment with an EGFR inhibitor, of which, 1 patient had a partial response, 3 patients had stable disease, and 1 patient had progressive disease, corresponding to a disease control rate of 80%. The trial has now moved to the Phase 2 portion, and will examine the antitumor activity and safety of PX-866 in combination with cetuximab versus cetuximab alone.

The Phase 2 portion will evaluate PX-866 at the dose determined in Phase 1 (8 mg), in combination with Erbitux, versus Erbitux alone, in colorectal and head & neck cancer patient’s naïve to Erbitux. The trial will randomize and evaluate up to 160 patients in two 72-patient groups, 36 in each of the PX-866 plus Erbitux and 36 in the Erbitux-alone arms. The first group of patients will enroll patients with metastatic colorectal cancer who have a history of progression or recurrence following treatment with irinotecan and oxaliplatin containing regimens or who are intolerant to irinotecan, and patients with KRAS mutations will be excluded. The second group will consist of patients with progressive, recurrent or metastatic SCCHN. The primary endpoint of the Phase 2 part of the trial is ORR based on RECIST criteria and secondary endpoints include PFS and OS, duration of response and disease control rate.



Phase 2 Trials in Collaboration with National Cancer Institute of Canada In collaboration with the National Cancer Institute of Canada Clinical Trials Group, Oncothyreon initiated a third Phase 2 trial evaluating PX-866 monotherapy in relapsed glioblastoma in 1Q11. The study is an open-label, single-arm trial evaluating a daily 8 mg oral dose of PX-866 in approximately 30 patients. The primary endpoint is to measure the objective response and early progression rates as assessed by CT scan or MRI. Secondary endpoints include safety and tolerability and determining the relationship between response and molecular markers in archival tissue from glioblastoma patients. According to management, preliminary results and an abstract have been submitted for presentation at the 2012 ASCO meeting. A fourth, single-arm, open-label Phase 2 trial, in collaboration with the National Cancer Institute of Canada Clinical Trials Group, began enrollment in 3Q11, and will evaluate PX-866 monotherapy in approximately 50 castrate-resistant prostate cancer naïve to chemotherapy. The primary endpoint of the study is efficacy based on the degree of stable disease observed following 12 weeks of PX-866 therapy. Secondary endpoints include safety, PSA response and response rate, objective response rate, change in circulating tumor cell counts, and the exploration of biomarkers predictive of response by analysis of archival prostate tumor tissue. According to clinicaltrials.gov, the study could report preliminary results in 2H13. PX-866 – A Future Revenue Generator With the Stimuvax program being carried forward by Merck KGaA, Oncothyreon is focused internally on developing the small molecule oncology drug candidate PX-866, an irreversible inhibitor of one of the most interesting and important targets in cancer, PI3 kinase (PI3K). The PX-866 program is fully owned by Oncothyreon and positive data from this program could make it an attractive candidate for a future partnership, given the demonstrated interest from Big Pharma and Big Biotech in PI3K as a target. The phosphatidylinositol-3 kinase PI3K/PTEN/Akt pathway is an important survival signaling pathway that is activated in many types of human cancer. Oncothyreon’s candidate PI3K inhibitor PX-866 induces prolonged inhibition of tumor PI3K signaling following both oral and intravenous administration and has been shown to have good in vivo anti-tumor activity in ovarian cancer, lung cancer, and intracranial glioblastoma tumor models in animals. PX-866 is an irreversible inhibitor with nanomolar potency that produces prolonged inhibition of the target and leads to suppression of downstream proteins in several key cellular pathways (Figure 5), with the potential to translate into significant pharmacokinetic and pharmacodynamic advantages in the clinic. Importantly, our analysis of R&D databases shows that majority of other PI3K inhibitors in clinical development are reversible inhibitors, which would necessitate large doses and more frequent administration as compared to PX-866.

Figure 5: PX-866 Inhibits PI3K


In preclinical studies examining human xenografts in mice, PX-866 inhibited growth of ovarian tumors as a single agent, and showed increased activity in lung cancer when administered in combination with Iressa. Additionally, Phase 1 pharmacodynamic data indicated that PX-866 lowers PBMC p-mTOR (phosphorylated mTOR) in a dose dependent manner as shown by data from patients in the 1 mg/day (cycles 1 & 2) and the 2 mg/day (cycle 1 only) dose cohorts (Figure 6). Of note, mTor is a downstream protein in the PI3-kinase pathway, and these data demonstrate that PX-866 is inhibiting the phosphorylation of mTOR at the 2 mg dose. These data, albeit early, appear to indicate that the drug is having the expected pharmacodynamic effects.



Figure 6: PX-866 Lowers PBMC p-mTOR from Patients in a Dose Dependent Fashion

Source: Poster presented at AACR, Nov, 2008.

Oncothyreon Licenses Sabutoclax – an Anti-Bcl-2 Compound Sabutoclax is a pan-inhibitor of Bcl-2 and is thought to function by sensitizing tumor cells to apoptosis

1. Sabutoclax is

currently in preclinical development with Oncothyreon, and is now being referred to as ONT-701. Under the terms of the sabutoclax license agreement, Oncothyreon made an upfront payment of $1.5 MM to Sanford-Burnham. Oncothyreon may be required to pay an additional $26 MM upon certain clinical milestones and up to $25 MM based on certain net sales targets in addition to low to mid single digit royalty on net sales. The management reported that the IND for ONT-701 is expected to be filed in 2013.

ONCOTHYREON’S THERAPEUTIC PIPELINE PORTFOLIO

DRUG PHASE(S) INDICATIONS RIGHTS

Stimuvax 3 NSCLC Oncothyreon / Merck KGaA

PX-866 2 Head & Neck, NSCLC, Prostate Cancer,

Glioblastoma Oncothyreon

ONT-10 1 NSCLC Oncothyreon / Merck KGaA has right of first

negotiation

ONT-701 Preclinical Under Review Oncothyreon / Sanford-Burnham Medical

Research Institute

Source: Oncothyreon

INVESTMENT PROS AND CONS The major investment pros and cons, as we see them, are summarized in the following table:

POSITIVES NEGATIVES

Stimuvax is being evaluated in two Phase 3 trials in NSCLC and has already been partnered with Merck KGaA, eliminating clinical development costs from Oncothyreon’s budget while

retaining significant upside by virtue of high-single digit royalties in the EU and mid-teens royalties in the US

Despite promising Phase 2 data, Stimuvax has not demonstrated an overall survival benefit in a Phase 3 trial

Stimuvax addresses a significant unmet need in NSCLC as well as a substantial market opportunity

Company will likely require additional capital to fund operations beyond 2H13

The next most advanced program PX-866, targets a central molecule implicated in cancer, PI3K, and is being broadly

evaluated in Phase 2 trials in head & neck, NSCLC, prostate cancer, glioblastoma

PX-866 will have to be tested in a large Phase 3 program and

will probably need a partner before entering Phase 3

Source: Rodman & Renshaw Research

1 Dash R et. al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc

Natl Acad Sci U S A. 2011 May 24;108(21):8785-90. Epub 2011 May 9.



INVESTMENT OPINION We are reiterating our Market Outperform rating and 12-month price target of $10 per share for Oncothyreon. Our price target is based on a 2015 discounted revenues and earnings per share multiples analysis. Although the second interim analysis did not live up to investor’s expectations, we continue to believe in the Stimuvax story. The recent data highlights the therapeutic value of Stimuvax, and also serves to validate Oncothyreon’s MUC1 based vaccine technology platform. In addition to Stimuvax and ONT-10, Oncothyreon possesses a broad oncology pipeline, which includes PX-866 (an irreversible inhibitor of PI3K) and ONT-701 (a newly acquired pan Bcl-2 inhibitor).

EXPECTED NEWSWORTHY EVENTS/MILESTONES FOR 2012 / 2013

Stimuvax

Potential for Merck KGaA to report outcome of second interim look for Phase 3 START trial (1Q12) - Potential for Merck KGaA to report top-line data from Phase 3 START trial (2013) - Potential for Merck KGaA to file BLA and MAA for Stimuvax (2013) - Potential for FDA to approve Stimuvax (2H13/2014) - Potential for EMA to approve Stimuvax (2H13/2014)

PX-866

- Potential to report preliminary data from Phase 2 trial in relapsed glioblastoma by NCI of Canada (2Q12) - Potential to report data from Phase 1/2 trial in combination with docetaxel in NSCLC and head & neck cancer

(4Q12) - Potential to report data from Phase 1/2 trial in combination with Erbitux in colorectal and head & neck cancer

(4Q12) ONT-10

- Potential to initiate Phase 1 trial (1H12) ONT-701

- Potential to submit IND application (2013)

FINANCIALS

REVENUES The potential for marketing and approval of Stimuvax represents the principal near-term revenue driver for Oncothyreon. In spite of today’s announcement of second interim analysis by Merck KGaA that lowered expectations of investors , we continue to maintain our projections for future Stimuvax sales and royalties. We believe that the BLA and MAA filings for Stimuvax should occur in 2013 with a potential market launch in the US in late 2013 and the EU in 2014. In the US, we have modeled a net royalty rate of 12% to Oncothyreon which takes into account a mid-single digit royalty payable by Oncothyreon to the original licensor of the MUC1 antigen, the patent for which expires in 2018. The royalty rate is higher in the US to compensate for Oncothyreon’s relinquishing of the company’s prior co-promotion interest in US and Canadian sales. In the EU, we have modeled a slightly lower royalty rate of 9%. In addition to royalty income, we model regulatory and commercial milestones for Stimuvax. Of note, the company has guided for splitting the additional $90 MM in milestones from Merck KGaA roughly 1/3 for regulatory filing, 1/3 approval and 1/3 for sales-based milestones, which are then split by 1

st and 2

nd indication as well as by region. Additionally, the value of the milestones

for the 1st indication is greater than the 2

nd indication. Based on this guidance, in 2013 we are assuming $9 MM each for

BLA and MAA filing for NSCLC and in 2013 we are assuming $9 MM for FDA approval and $9 MM for EMA approval in 2014. We model additional sales-based milestones in 2014 and 2015 for the NSCLC indication. The potential to partner PX-866 could generate additional licensing revenue and represent upside not reflected in our model. Based on the above assumptions and the 2011 performance, our revenue estimates for 2012-2015 are $0.0 MM, $43.1 MM, $91.4 MM and $137.4 MM, respectively.



EXPENSES COGS As all manufacturing process development costs have been borne by Merck KGaA since December 18, 2008, Oncothyreon has no further obligations to produce Stimuvax and no COGS are expected upon commercial launch. R&D In 4Q11, the company reported R&D expenses of $4.1 MM, lower than our estimate of $6.4 MM. We believe that Oncothyreon will continue to advance PX-866 through Phase 2 and potentially Phase 3 trials, as well as further develop ONT-10, using potential future royalty income generated from sales of Stimuvax. Going forward, our 2012 R&D estimate is $24.7 MM. SG&A In 4Q11, the company reported SG&A expenses of $2.4 MM, significantly higher than our estimate of $1.0 MM. Based on the guidance, our 2012 SG&A estimate is $9.9 MM. NET INCOME (LOSS) AND EPS For 4Q11, Oncothyreon reported a net loss of $11.5 MM or $(0.27) per diluted share, lower than our net loss estimate of $12.4 MM or $(0.30) per share, as a result of change in valuation of a warrant liability. Based on the above assumptions and future revenues and expenses, our 2012 net income (loss) estimate is $(36.2) MM or $(0.83) per share. CASH At the end of 4Q11, the company had approximately $66.4 MM in cash and cash equivalents, sufficient, in our opinion, to fund operations into 2013. As per the 4Q11 conference call, management expects the 2012 cash burn to be in the range of $30-$33 MM.

INVESTMENT RISKS As with most investments in development-stage biopharmaceutical companies, especially in the small to mid-cap space, investing in Oncothyreon shares involves significant clinical, regulatory, and commercial risks. We therefore recommend Oncothyreon shares to risk-tolerant and experienced biotech and healthcare investors, as we believe that the risk/reward offered by this stock would be more appropriate for that type of investor. Risks that are specific to Oncothyreon include: Clinical Risk: Although the Phase 2 trial evaluating Stimuvax showed promising results, the data were not statistically significant and the Phase START trial could still fail. Additionally, while PX-866 has only recently entered Phase 2 evaluation and the data may not be sufficiently compelling to merit advancement into Phase 3 studies. Regulatory Risk: The company’s clinical trial results may not be sufficiently compellingly to convince regulatory agencies of clinical benefit relative to the side effect profile, leading to request for additional studies and/or non-approval of the company’s products. Commercialization Risk: The company’s products may not obtain the market penetration and sales forecasted by our estimates or those of the company given the established marketplace for existing competitive products. Financial Risk: The company may have insufficient funds to complete the development and commercialization strategy of its pipeline products. With approximately $66.4 MM in cash, in our opinion Oncothyreon has sufficient resources to fund operations through 2013. The company will likely need to seek additional dilutive financing via the capital markets. Market Risk: Small-cap biotechnology stocks are inherently volatile and often illiquid. They are not appropriate for investors with a low-risk profile.



ONCOTHYREON HISTORICAL INCOME STATEMENTS, FINANCIAL PROJECTIONS

Source: Oncothyreon Reports and Rodman and Renshaw Research

Figures in thousands $ except per share data

2010 1Q11 2Q11 3Q11 4Q11 2011 2012 2013 2014 2015

Revenues

Licensing, Royalties and Other Revenue - - - - - - - 16,115 76,391 125,377

Licensing Revenue from Collaborative Agreements 18 145 - - 145 27,000 15,000 12,000

Total Revenues 18 145 - - - 145 - 43,115 91,391 137,377

Expenses

Cost of Sales - - - - - - - - - -

Research and Development 11,241 4,188 4,193 5,383 4,151 17,915 24,756 32,419 42,145 52,681

General, Administrative and Other 7,799 1,829 1,633 1,060 2,407 6,929 9,871 11,077 16,616 24,924

Depreciation/Amortization 462 - - 448 448 448 448

Total Operating expenses 19,502 6,017 5,826 6,443 6,558 24,699 35,075 43,944 59,209 78,053

Other Expenses

Interest Expense - (99) (175) (179) (178) (631) 1,321 1,321 881 -

Change in Fair Value of Warrant Liability (3,030) (1,458) (28,023) 16,633 (4,783) (17,631) - - - -

Investment and Other Income/expense (636) 313 51 (74) 15 305 (150) (53) (92) (184)

Total Expenses 15,836 (7,261) (33,973) 9,937 (11,504) (42,656) 36,246 45,212 59,997 77,869

Earnings before Taxes (15,818) (7,116) (33,973) 9,937 (11,504) (42,656) (36,246) (2,097) 31,394 59,508

Provision for Income Tax (200) - - - - - - - 6,279 11,902

Net Income (Loss) (15,618) (7,116) (33,973) 9,937 (11,504) (42,656) (36,246) (2,097) 25,115 47,607

Basic EPS (0.58) (0.24) (0.91) 0.24 (0.27) (1.12) (0.84) (0.05) 0.57 1.07

Diluted EPS (0.58) (0.24) (0.91) 0.22 (0.27) (1.12) (0.84) (0.05) 0.53 1.00

Basic shares 26,889 30,089 37,434 41,929 43,154 38,198 43,404 43,804 44,204 44,604

Diluted shares 26,889 30,089 37,434 44,850 43,154 38,198 43,404 43,804 47,125 47,525

Rodman & Renshaw, LLC Ren Benjamin, Ph.D.

212-430-1743



ONCOTHYREON HISTORICAL BALANCE SHEET STATEMENTS


($ in million, except per-share amounts) 1Q11 2Q11 3Q11 4Q11

Cash and Cash Equivalents 11,008 51,036 11,000 66,407

Short-term Investments 17,990 15,796 48,616 -

Accounts Receivables 363 209 567 -

Government Grants Receivable - - - -

Notes Receivable - - - -

Prepaid Expenses 460 566 748 -

Total Current Assets 29,821 67,607 60,931 66,407

Long-term Investments 2,555 -

Plant and equipment, net 1,888 1,788 1,687 -

Lease deposits - - - -

Other Assets 306 287 269 -

Goodwill 2,117 2,117 2,117 -

Total Assets 34,132 71,799 67,559 71,351

Accounts Payable 939 639 465 -

Accrued Liabilities 865 1,102 943 -

Accrued compnesation 412 583 817 -

Current portion of notes payable 758 1,132 1,590 -

Current portion of deferred revenue - - - -

Current liabilities 2,974 3,456 3,815 -

Notes Payable 4,139 3,785 3,347 -

Deferred Revenue - - - -

Preferred Stock Redeemable 30 30 30 -

Deferred rent 400 412 618 -

Warrant Liability 14,441 42,464 23,988 -

Long term liabilities - - - 33,236

Total liabilities 21,984 50,147 31,798 -

Shareholders' Equity

Common Stock-par Value 353,851 353,851 353,851 -

Additional Paid in Capital 17,784 61,301 65,369 -

Accumulated Deficit (354,371) (388,344) (378,407) -

Accumulated Other Comprehensive Loss (5,116) (5,156) (5,052) -

Total Stockholders' Equity 12,148 21,652 35,761 33,433

Total Liabilities & Equity 34,132 71,799 67,559 33,433

* To be completed upon release of 10-K



RODMAN & RENSHAW RATING SYSTEM: Rodman & Renshaw employs a three tier rating system for evaluating both the potentialreturn and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on aRELATIVE basis of other companies in the same sector, as defined by First Call. The price objective is calculated to estimate the potentialmovement in price a given equity could achieve given certain targets are met over a defined time horizon. Price objectives are subject toexogenous factors including industry events and market volatility. The risk assessment evaluates the company specific risk and accountsfor the following factors, maturity of market, maturity of technology, maturity of firm, cash utilization, and valuation considerations.Potential factors contributing to risk: relatively undefined market, new technologies, immature firm, high cash burn rates, intrinsic valueweighted toward future earnings or events.

RETURN ASSESSMENT● Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the

common stock of companies within the same sector, as defined by First Call.● Market Perform (Hold): The common stock of the company is expected to mimic the performance of a passive index comprised

of all the common stock of companies within the same sector, as defined by First Call.● Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all

the common stock of companies within the same sector, as defined by First Call.

RISK ASSESSMENT● Speculative - The common stock risk level is significantly greater than market risk. The stock price of these equities is

exceptionally volatile.● Aggressive - The common stock risk level is materially higher than market level risk. The stock price is typically more volatile

than the general market.● Moderate - The common stock is moderately risky, or equivalent to stock market risk. The stock price volatility is typically in-line

with movements in the general market.

Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 Q10

3

6

9

12

2009 2010 2011 2012

03/18/09MO:$4

04/17/09MO:$6

08/03/09MO:$8

03/23/10UR:$8

05/21/10MO:$8

03/21/11UR:NA

04/25/11MO:$10

Rating and Price Target History for: Oncothyreon Inc. (ONTY) as of 03-08-2012

Created by BlueMatrix

RATING SUMMARY

Distribution of Ratings TableIB Serv./Past 12 Mos

Rating Count Percent Count PercentMarket Outperform(MO) 95 60.50% 15 15.79%Market Perform(MP) 31 19.70% 3 9.68%Market Underperform(MU) 6 3.80% 0 0.00%Under Review(UR) 25 15.90% 4 16.00%Total 157 100% 22 100%

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement ofsecurities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its



affiliates or subsidiaries within the past 12 months.

ADDITIONAL DISCLOSURESRodman & Renshaw, LLC. (the "Firm") is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

ANALYST CERTIFICATION

I, Reni Benjamin, Ph.D., hereby certify that the views expressed in this research report accurately reflect my personal views about thesubject company(ies) and its (their) securities.

None of the research analysts or the research analyst's household has a financial interest in the securities of Oncothyreon Inc. (including,without limitation, any option, right, warrant, future, long or short position).

As of Jan 31 2012 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of OncothyreonInc..

Neither the research analyst nor the Firm has any material conflict of interest with Oncothyreon Inc., of which the research analyst knowsor has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specificinvestment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, asubstantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Oncothyreon Inc. for any investment banking services within twelve monthsbefore, but intends to seek compensation from the companies mentioned in this report for investment banking services within threemonths, following publication of the research report.

Neither the research analyst nor any member of the research analyst's household nor the Firm serves as an officer, director or advisoryboard member of Oncothyreon Inc..

The Firm does make a market in Oncothyreon Inc. securities as of the date of this research report.

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.

Reproduction without written permission is prohibited. The closing prices of securities mentioned in this report are as of Mar 08 2012.Additional information is available to clients upon written request. For complete research report on Oncothyreon Inc., please call (212)356-0500.

Readers are advised that this analysis report is issued solely for informational purposes and is not to be construed as an offer to sell orthe solicitation of an offer to buy. The information contained herein is based on sources which we believe to be reliable but is notguaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performanceis no guarantee of future results.


rodman renshaw report on onty

Investor Relations

start trial

gbm trial

trial tocontinue

trial inq4

broad phase

ongoing phase

trials of px

openlabel phase